title: Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma.
abstract: OBJECTIVE
  The aim of this study was to obtain adriamycin-loaded polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody (PLNP-Mal-EGFR) for hepatocellular carcinoma (HCC) chemotherapy.
  
  
  METHODS
  The nanoparticles were characterized by dynamic light scattering and fluorescence spectroscopy. The in vitro and in vivo distribution and anti-tumor activity of the nanoparticles were evaluated.
  
  
  CONCLUSIONS
  PLNP-Mal-EGFR showed significantly enhanced cellular cytotoxicity against HCC cells overexpressing EGFR compared with nontargeted nanoparticles (polymer-lipid hybrid nanoparticles [containing DSPE-PEG-Mal] and polymer-lipid hybrid nanoparticles [containing DSPE-mPEG] combined with anti-EGFR Fab´). PLNP-Mal-EGFR and nontargeted nanoparticles could significantly reduce the proportion of side-population cells in HCC cells. The in vivo accumulation of PLNP-Mal-EGFR was obviously higher than that of nontargeted nanoparticles in SMMC-7721 HCC cells overexpressing EGFR. Notably, PLNP-Mal-EGFR showed significantly enhanced anti-tumor activity against HCC in vivo compared with nontargeted nanoparticles and free adriamycin. Therefore, PLNP-Mal-EGFR may serve as an effective therapeutic approach for HCC chemotherapy.
authors.affiliation: International Joint Cancer Institute, The Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Gao
authors.forename: Yu
authors.initials: Y
authors.lastname: Xia
authors.forename: Huaiwen
authors.initials: H
authors.lastname: Chen
authors.forename: Yongsheng
authors.initials: Y
authors.lastname: Yu
authors.forename: Jinjing
authors.initials: J
authors.lastname: Song
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Weizhu
authors.initials: W
authors.lastname: Qian
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.forename: Jianxin
authors.initials: J
authors.lastname: Dai
authors.forename: Yajun
authors.initials: Y
authors.lastname: Guo
mesh_terms: D000906:Antibodies / Q000276:immunology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000276:immunology*; D008055:Lipids / Q000737:chemistry; D008113:Liver Neoplasms / Q000188:drug therapy*; D018613:Microscopy, Confocal; D053758:Nanoparticles; D011108:Polymers / Q000737:chemistry
chemical_list: D000906:Antibodies; D008055:Lipids; D011108:Polymers; D066246:ErbB Receptors